VALN
What one share of Valneva SE holds
Biological Products, (No Diagnostic Substances)
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best-, or only-in-class vaccine solutions.
Valneva SE’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $2.35 |
|---|---|
| Profit | −$1.55 |
| Capex (buildings and equipment) | $0.06 |
| Free cash flow | −$0.77 |
| Cash and investments | $1.48 |
| Debt | $2.42 |
| Book value | $1.44 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $2.77 | −$1.62 | $0.48 | $2.99 | — | $2.08 |
| 2022 | $6.59 | −$2.61 | $0.53 | −$5.01 | — | $3.40 |
| 2023 | $2.40 | −$1.58 | $0.22 | −$3.39 | — | $2.04 |
| 2024 | $2.52 | −$0.18 | $0.21 | −$1.20 | — | $2.31 |
| 2025 | $2.35 | −$1.55 | $0.06 | −$0.77 | — | $1.44 |